A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune Thrombocytopenia
Latest Information Update: 27 Jul 2023
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Proof of concept
- Sponsors argenx
- 10 Dec 2019 Results (n=38) assessing safety and efficacy of efgartigimod in adult patients with primary immune thrombocytopenia, presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 03 May 2019 Status changed from active, no longer recruiting to completed.
- 12 Dec 2018 This trial was completed in Czech Republic, according to European Clinical Trials Database.